Reaction mass of 3-({[2,2-dimethyl-3-({[2-(2-{[(prop-2-en-1-yloxy)carbonyl]oxy}ethoxy)ethoxy]carbonyl}oxy)propoxy]carbonyl}oxy)prop-1-ene and 3-{[(2,2-dimethyl-3-{[(prop-2-en-1-yloxy)carbonyl]oxy}propoxy)carbonyl]oxy}prop-1-ene and diallyl 2,2'-oxydiethyl dicarbonate

Basic toxicokinetics

Administrative data

Endpoint:

basic toxicokinetics

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

comparable to guideline study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1983

Materials and methods

Objective of study:

excretion

Test guideline

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 417 (Toxicokinetics)

Deviations:

yes

Principles of method if other than guideline:

Three animals were used. No sufficient information about test substance, experimental animals, their housing and feeding conditions. One dose level of test substance was administered. No interpretation of results.

GLP compliance:

no

Test material

Test material information

Constituent 1

Reference substance name:

Diallyl 2,2'-oxydiethyl dicarbonate

EC Number:

205-528-7

EC Name:

Diallyl 2,2'-oxydiethyl dicarbonate

Cas Number:

142-22-3

Molecular formula:

C12H18O7

IUPAC Name:

diallyl 2,2'-oxydiethyl dicarbonate

Details on test material:

- Name of test material (as cited in study report): 14C Labeled Diallyl-Diglycol Carbonate
- Radiochemical purity (if radiolabelling): Scintillation counting determinations showed that a 100 microliter dose contained 0.97 microcuries of 14C labeled test substance.
- Locations of the label (if radiolabelling): (allyl-14C1) moiety of diallyl-diglycol
- Other: The 14C labeled test substance utilized in this study was synthesized by New England Nuclear and was provided by the sponsor. A precipitant formed when the material was dissolved in absolute EtOH (ethanol). The EtOH soluble fraction was assayed by thin layer chromatography using Silica Gel G. and a hexane:ether (40:60, v/v) solvent system. The EtOH soluble fraction had the same rf value as a test substance reference standard. Only the EtOH soluble fraction was used in these studies.

Radiolabelling:

yes

Remarks:

14C

Test animals

Species:

guinea pig

Strain:

not specified

Sex:

not specified

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: data not available
- Age at study initiation: adult animals
- Weight at study initiation: data not available
- Fasting period before study: data not available
- Housing: individually
- Individual metabolism cages: yes
- Diet (e.g. ad libitum): data not available
- Water (e.g. ad libitum): data not available
- Acclimation period:data not available

ENVIRONMENTAL CONDITIONS
data not available

Administration / exposure

Route of administration:

intramuscular

Vehicle:

ethanol

Details on exposure:

TYPE OF EXPOSURE: intramuscular

Duration and frequency of treatment / exposure:

single dose

Doses / concentrations

Remarks:

Doses / Concentrations:
100 µL

No. of animals per sex per dose / concentration:

3

Control animals:

no

Positive control reference chemical:

no

Details on study design:

- Dose selection rationale: not reported
- Rationale for animal assignment (if not random): not applicable

Details on dosing and sampling:

PHARMACOKINETIC STUDY ( excretion)
- Body fluids sampled (delete / add / specify): urine, faeces and respirated carbon dioxide
- Time and frequency of sampling: daily for 7 days
- Method type(s) for identification: (Liquid scintillation counting)


METABOLITE CHARACTERISATION STUDIES
- Tissues sampled: liver, kidney, thigh (site of injection)
- Time and frequency of sampling: at termination
- From how many animals: (samples pooled) 3
- Method type(s) for identification: wet ashing method of Bucks and Maibach
- Limits of detection and quantification: data not available

Statistics:

not reported

Results and discussion

Preliminary studies:

The present study is conducted according to a research proposal; no further data available.

Toxicokinetic / pharmacokinetic studies

Details on absorption:

not applicable

Transfer into organs

Transfer type:

other: not applicable (excretion study)

Observation:

other: not applicable (excretion study)

Toxicokinetic parameters

Toxicokinetic parameters:

other: not measured

Metabolite characterisation studies

Metabolites identified:

not measured

Details on metabolites:

not applicable

Any other information on results incl. tables

Table 1: Recovery % of test substance

	Animal 1	Animal 2	Animal 3
Urine*	20.41	18.75	20.57
Feces	9.15	6.82	3.67
CO2**	70.77	70.77	70.77
Kidneys	0.08	0.16	0.16
Livers	1.62	0.21	4.46
Carcass	6.44	3.24	4.61
Thigh***	2.89	6.14	7.43
Summe	111.36	106.09	111.67

* percent of applied 14C dose

** carbon dioxide was a pooled animal collection

*** site of IM (intramuscular) injection

The total percent recovery of the compound was 109.7 (standard deviation of 3.1). The excess above 100% is due to extremely low counts above background, large volumes of the tissue homogenate preparations and the small aliquot utilized in the wet ashing procedure.

The 14C label on the test substance was predominately excreted via respiration (70 .77% of the injected dose). Over 60% of the dose was collected in the respired carbon dioxide within the first 24 hours from application.

Elimination of the 14C label on the test substance into the urine accounts for 19.9% (standard deviation of 1.0) of the dose with 19% of the dose being eliminated within the first 24 hours from application.

Applicant's summary and conclusion

Conclusions:

Interpretation of results: no bioaccumulation potential based on study results (only one dose level was tested).
Based on the study results, there was no retention of the test substance in organs examined. The test substance was predominantly excreted via respiration.

Executive summary:

This study was performed to determine the excretion parameters of the allyl-14C1- label on diallyl-diglycol carbonate into the urine, feces, and respired carbon dioxide as well as deposition into the liver, kidney, thigh (site of injection), and remaining carcass following a single parenteral dose utilizing the guinea pig experimental animal model.

The percent recovery of the test substance in parameters examined was 100% seven days after the administration.